Glaukos Corporation (NYSE: GKOS) has completed patient enrollment in a Phase 2 clinical study evaluating GLK-321, an investigational drug candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE